What is the life expectancy of someone with Pseudomyxoma Peritonei?

Pseudomyxoma peritonei (PMP) is a rare condition characterized by the accumulation of mucinous fluid in the abdomen, and while prognosis varies significantly based on tumor grade and treatment, many patients now achieve long-term survival due to specialized surgical interventions. Life expectancy is not defined by a single statistic, as outcomes depend heavily on the biological behavior of the underlying appendiceal tumor, the completeness of surgical resection, and access to expert care.

What factors influence the prognosis of Pseudomyxoma Peritonei?

The prognosis for Pseudomyxoma peritonei is highly individualized. Factors that influence life expectancy include the histological grade of the mucinous tumor (low-grade vs. high-grade), the volume of disease at the time of diagnosis, and the patient's overall health. Because Pseudomyxoma peritonei is often slow-growing, many individuals live for many years following diagnosis, particularly when managed by surgical oncologists who specialize in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

How have treatment advances changed outcomes for patients?

Over the past three decades, the management of Pseudomyxoma peritonei has evolved from palliative care to aggressive, curative-intent protocols. Improvements in imaging, surgical techniques, and targeted chemotherapy have significantly extended survival rates for those with Pseudomyxoma peritonei. Currently, specialized centers report that patients who undergo successful complete cytoreduction often experience long-term disease control.

What should I know about quality of life and long-term care?

Longevity is only one part of the journey. For the 110 members of the DiseaseMaps community living with Pseudomyxoma peritonei, quality of life remains a priority. Managing symptoms through multidisciplinary care—including pain management, nutrition, and psychological support—is essential. Key aspects of long-term monitoring include:

• Regular surveillance using tumor markers (such as CEA, CA 19-9, and CA-125).


• Serial CT or MRI imaging to detect early recurrence.


• Consistent follow-up with a multidisciplinary team familiar with the nuances of Pseudomyxoma peritonei.


• Active participation in specialized patient communities for peer support and shared experiences.

Next steps

• Consult with a surgical oncologist who specializes in peritoneal surface malignancies.


• Request a pathology review at a high-volume center to confirm the histological subtype of your Pseudomyxoma peritonei.


• Connect with the DiseaseMaps.org community to share experiences and coping strategies with others navigating this rare disease.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Pseudomyxoma peritonei.


• Orphanet: Pseudomyxoma peritonei (ORPHA: 761).


• PMP Pals: Resources for patients and families affected by Pseudomyxoma peritonei.


• PubMed: Clinical studies on cytoreductive surgery and HIPEC outcomes.